Fragmentomics company whose FirstLook Lung blood test aims to raise lung-cancer screening uptake; first randomised clinical-utility data in 2026.
FirstLook Lung (launched 2023) analyses cfDNA fragmentation patterns to identify who should proceed to low-dose CT. The L301 FIRSTLUNG cluster-randomised trial (NCT06145750) was presented as a late-breaker at ATS 2026; AACR 2026 showed whole-genome cfDNA advances in detection and monitoring. Johns Hopkins spin-out.
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Illumina Ventures, Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares cfDNA fragmentomics, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/